Remove FDA Remove Medicine Remove Pharmacology
article thumbnail

Psychedelic medicines: are they gaining traction in Europe?

European Pharmaceutical Review

6 Therefore, the quality of data provided to regulators will be key in obtaining MAs and subsequently marketing of psychedelic medicines. 6 Therefore, the quality of data provided to regulators will be key in obtaining MAs and subsequently marketing of psychedelic medicines.

Medicine 131
article thumbnail

First-in-class therapy approved for schizophrenia

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for schizophrenia in adults. Bristol Myers Squibb highlighted that Xanomeline is a dual M 1 – and M 4 -preferring muscarinic receptor agonist.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA drug dosage optimisation guidelines signal clinical trial reform

Pharmaceutical Technology

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The focus on identifying the ideal drug dosage is not new.

FDA 115
article thumbnail

Two novel biosimilars approved in EU and US

European Pharmaceutical Review

As such, the FDA stated that the monoclonal antibody Bkemv has approval for use in the following conditions: Paroxysmal nocturnal haemoglobinuria (PNH) to reduce haemolysis Atypical haemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

On February 7, at a town hall organised to discuss clinical trial designs for gene therapies, FDA experts pushed pharma players to look for ways to establish clinical effectiveness despite the challenges in recruiting patients with rare diseases.

FDA 105
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few? 3 Is two too few?

Marketing 103
article thumbnail

Abliva’s NV354 receives ODD from US FDA

Pharma Leaders

Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial disease. Abliva is a clinical-stage company developing medicines to treat rare and severe primary mitochondrial diseases.

FDA 52